title: Prospects for the Use of ATR Inhibitors to Treat Cancer.
abstract: ATR is an apical kinase in one of the DNA-damage induced checkpoint pathways. Despite the development of inhibitors of kinases structurally related to ATR, as well as inhibitors of the ATR substrate Chk1, no ATR inhibitors have yet been developed. Here we review the effects of ATR downregulation in cancer cells and discuss the potential for development of ATR inhibitors for clinical use.
authors.affiliation: Division of Oncology Research, College of Medicine, Mayo Clinic, 200 First St., S.W., Rochester, MN 55905, USA. wagner.jill@mayo.edu.
authors.forename: Jill M
authors.initials: JM
authors.lastname: Wagner
authors.affiliation: Division of Oncology Research, College of Medicine, Mayo Clinic, 200 First St., S.W., Rochester, MN 55905, USA. kaufmann.scott@mayo.edu.
authors.forename: Scott H
authors.initials: SH
authors.lastname: Kaufmann
keywords: ATM; ATR; Chk1; Replication checkpoint; chemotherapy